Literature DB >> 3027581

A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia.

L C Chan, K K Karhi, S I Rayter, N Heisterkamp, S Eridani, R Powles, S D Lawler, J Groffen, J G Foulkes, M F Greaves, L M Wiedemann.   

Abstract

The Philadelphia (Ph) chromosome breakpoints in chronic myelocytic leukaemia are clustered on chromosome 22 band q11 in a 5.8-kilobase (kb) region designated bcr. The c-abl protooncogene is translocated from chromosome 9 band q34 into bcr and the biochemical consequence of this molecular rearrangement is the production of an abnormal fusion protein bcr-abl p210 with enhanced protein-tyrosine kinase activity compared to the normal p145 c-abl protein. The Ph chromosome translocation is also seen in some acute lymphoblastic leukaemias with B-cell precursor phenotypes some of which have bcr rearrangement (bcr+) and some do not (bcr-). We present evidence that the Ph+, bcr- leukaemias are associated with a novel p190 abl kinase. We propose that acute lymphoblastic leukaemias that are bcr+, p210+ are probably lymphoid blast crises following a clinically silent chronic phase of chronic myelocytic leukaemia arising in multipotential stem cells whereas bcr-, p190+ cases are de novo acute lymphoblastic leukaemias arising in more restricted precursors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3027581     DOI: 10.1038/325635a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  46 in total

1.  Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia.

Authors:  S Eridani; L M Wiedemann; L C Chan; R G Dalton; K K Karhi
Journal:  Cytotechnology       Date:  1987-10       Impact factor: 2.058

2.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.

Authors:  J R McWhirter; J Y Wang
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

Review 3.  Molecular analysis of the Philadelphia chromosome.

Authors:  A Dobrovic; G B Peters; J H Ford
Journal:  Chromosoma       Date:  1991-09       Impact factor: 4.316

Review 4.  BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Authors:  Wanlong Ma; Hagop Kantarjian; Chen-Hsiung Yeh; Zhong J Zhang; Jorge Cortes; Maher Albitar
Journal:  Acta Haematol       Date:  2009-03-31       Impact factor: 2.195

5.  Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.

Authors:  Charles G Mullighan; Richard T Williams; James R Downing; Charles J Sherr
Journal:  Genes Dev       Date:  2008-06-01       Impact factor: 11.361

6.  Mechanism of activation of the human trk oncogene.

Authors:  F Coulier; D Martin-Zanca; M Ernst; M Barbacid
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

7.  Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  C T Denny; N P Shah; S Ogden; C Willman; T McConnell; W Crist; A Carroll; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

8.  A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.

Authors:  E Freed; T Hunter
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

9.  Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.

Authors:  M Wetzler; M Talpaz; R A Van Etten; C Hirsh-Ginsberg; M Beran; R Kurzrock
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

10.  Development and targeted use of nilotinib in chronic myeloid leukemia.

Authors:  Carmen Fava; Hagop Kantarjian; Jorge Cortes; Elias Jabbour
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.